Alzheimer Disease

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

Lecanemab (Lequembi) approved to treat mild cognitive impairment or mild dementia associated with Alzheimer disease.

Indication can play a major role in pharmacists recommending brain health products.

White adults in their midlife showed slower brain aging than Black and Latinx individuals, but between mid- and late life, they showed increased signs of aging.

Legislation expands protection of original 1965 act to individuals younger than 60 years.

Patients with Alzheimer disease administered gantenerumab did experience slower clinical decline, however, it was not deemed statistically significant.

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Patients with type 2 diabetes may lower their risk of developing severe neurological disorders like Alzheimer disease by taking certain anti-diabetic medications alongside daily insulin.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

Antioxidants are capable of converting highly destructive free radicals and nonradical molecules, thereby reducing cerebral stress.

The history of targeting neuroinflammation is a good example of the challenges to finding a treatment for Alzheimer disease.

In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.

A recent study revealed that social activities like gardening or getting a college degree could improve cognition in older age, which could possibly prevent Alzheimer disease.

Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Statistics indicate possible benefit of home-based palliative care interventions, according to study results from the Indiana University School of Medicine and the Regenstrief Institute.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

Using a transgenic mouse model of Alzheimer’s disease, scientists demonstrate a definitive connection with oxidative brain damage.

Tau protein, plaque, and brain waves maybe the solutions to treating the progressive condition.

When using a therapy to clear the senescent cells, disease progression and cell death were stopped, according to the study.

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.

Although the test does not definitively diagnose problems such as Alzheimer disease, it helps physicians get a baseline of their patients’ cognitive functioning.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Alzheimer disease.

Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.

The report also describes the benefits of interventions at the family, individual, institutional, organizational, and policy levels and differentiates AD from other types of dementia.

It is an FDA-approved-agent agnostic approach to gathering routine clinical practice data and outcomes for sharing and transparency.